Mitazalimab synergizes with chemotherapy – Alligator Bioscience presents new preclinical data at AACR

On March 11, 2021 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that an abstract for a poster presentation at the AACR (Free AACR Whitepaper) (American Association for Cancer Research) Annual Meeting 2021, presenting new preclinical data for the clinical asset mitazalimab, is now released (Press release, Alligator Bioscience, MAR 11, 2021, View Source [SID1234576467]). The AACR (Free AACR Whitepaper) Annual Meeting 2021 will be held in a virtual format over two one-week periods in April and May 2021. Alligator Bioscience’s abstract will be presented in an ePoster session during April 10-15.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alligator Bioscience has previously shown that mitazalimab synergizes effectively with immune checkpoint inhibitors and vaccines. The abstract, titled "Mitazalimab, a potent CD40 agonist with potential for combination with chemotherapy", demonstrates that mitazalimab synergizes with chemotherapy, notably FOLFIRINOX, leading to improved long-term survival in a preclinical tumor model.

"The new preclinical data are very encouraging. Together with the clinical data of mitazalimab from a previous Phase I study, where mitazalimab was well tolerated up to 1200 µg/kg, these data support the upcoming clinical Phase II study of mitazalimab in combination with chemotherapy in pancreatic cancer patients," says Per Norlén, CEO of Alligator Bioscience.

Mitazalimab is a human CD40 agonistic antibody developed for immunotherapy of cancer. The chemotherapy cocktail FOLFIRINOX kills tumor cells leading to increased release of tumor antigens. Activation of CD40 leads to improved presentation of tumor antigens, and the consequent T cell priming and initiation of T cell-dependent anti-tumor responses.